JP7843245B2 - ペプチドタグおよび結合パートナー - Google Patents

ペプチドタグおよび結合パートナー

Info

Publication number
JP7843245B2
JP7843245B2 JP2022567869A JP2022567869A JP7843245B2 JP 7843245 B2 JP7843245 B2 JP 7843245B2 JP 2022567869 A JP2022567869 A JP 2022567869A JP 2022567869 A JP2022567869 A JP 2022567869A JP 7843245 B2 JP7843245 B2 JP 7843245B2
Authority
JP
Japan
Prior art keywords
seq
tag
peptide
binding partner
peptide tag
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022567869A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023525752A (ja
JP2023525752A5 (https=
Inventor
フージュルー，シリエル，エリエット
バーテルセン，アダム，フレデリック，サンダー
トラーネ，スーザン
Original Assignee
アダプトヴァク エーピーエス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アダプトヴァク エーピーエス filed Critical アダプトヴァク エーピーエス
Publication of JP2023525752A publication Critical patent/JP2023525752A/ja
Publication of JP2023525752A5 publication Critical patent/JP2023525752A5/ja
Priority to JP2025267995A priority Critical patent/JP2026048917A/ja
Application granted granted Critical
Publication of JP7843245B2 publication Critical patent/JP7843245B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
JP2022567869A 2020-05-07 2021-05-07 ペプチドタグおよび結合パートナー Active JP7843245B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025267995A JP2026048917A (ja) 2020-05-07 2025-12-19 ペプチドタグおよび結合パートナー

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20173377.1 2020-05-07
EP20173377 2020-05-07
PCT/EP2021/062113 WO2021224451A1 (en) 2020-05-07 2021-05-07 Peptide tags and binding partners

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025267995A Division JP2026048917A (ja) 2020-05-07 2025-12-19 ペプチドタグおよび結合パートナー

Publications (3)

Publication Number Publication Date
JP2023525752A JP2023525752A (ja) 2023-06-19
JP2023525752A5 JP2023525752A5 (https=) 2024-05-15
JP7843245B2 true JP7843245B2 (ja) 2026-04-09

Family

ID=70613720

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022567869A Active JP7843245B2 (ja) 2020-05-07 2021-05-07 ペプチドタグおよび結合パートナー
JP2025267995A Pending JP2026048917A (ja) 2020-05-07 2025-12-19 ペプチドタグおよび結合パートナー

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025267995A Pending JP2026048917A (ja) 2020-05-07 2025-12-19 ペプチドタグおよび結合パートナー

Country Status (11)

Country Link
US (1) US20230321260A1 (https=)
EP (1) EP4146675A1 (https=)
JP (2) JP7843245B2 (https=)
KR (1) KR20230006473A (https=)
CN (1) CN115698045A (https=)
AU (1) AU2021268757A1 (https=)
BR (1) BR112022019632A2 (https=)
CA (1) CA3177709A1 (https=)
IL (1) IL297111A (https=)
MX (1) MX2022013938A (https=)
WO (1) WO2021224451A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016112921A1 (en) 2015-01-15 2016-07-21 University Of Copenhagen Virus-like particle with efficient epitope display
WO2022229817A1 (en) * 2021-04-28 2022-11-03 Bavarian Nordic A/S Vaccines comprising virus-like particles displaying sars-cov-2 antigens and methods of use
US20240240203A1 (en) 2021-05-04 2024-07-18 SpyBiotech Limited Adenoviral vectors and vaccines thereof
EP4593874A2 (en) 2022-09-30 2025-08-06 Bavarian Nordic A/S Virus-like particles displaying sars-cov-2 antigens as booster vaccines and uses thereof
CN116165377A (zh) * 2023-04-21 2023-05-26 常州伯仪生物科技有限公司 一种通过竞争elisa法进行标签蛋白定量的方法
WO2025097030A1 (en) * 2023-11-02 2025-05-08 Oregon State University Virus-like particles displaying neisseria gonorrhoeae antigens and use thereof for immunization against gonorrhea
GB202317925D0 (en) 2023-11-23 2024-01-10 Spybiotech Ltd Vaccines
CN117723749B (zh) * 2024-02-07 2024-06-04 南昌大学 基于分子粘合剂的动态光散射免疫传感检测方法
WO2026039325A2 (en) 2024-08-12 2026-02-19 Regeneron Pharmaceuticals, Inc. Modified mtm1 genes and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016112921A1 (en) 2015-01-15 2016-07-21 University Of Copenhagen Virus-like particle with efficient epitope display
JP2018521640A (ja) 2015-06-05 2018-08-09 オックスフォード ユニバーシティ イノベーション リミテッドＯｘｆｏｒｄ Ｕｎｉｖｅｒｓｉｔｙ Ｉｎｎｏｖａｔｉｏｎ Ｌｉｍｉｔｅｄ 融合タンパク質を合成するための方法および製品

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201002362D0 (en) 2010-02-11 2010-03-31 Isis Innovation Peptide tag systems that spontaneously form an irreversible link to protein partners via isopeptide bonds
PL3215614T3 (pl) * 2014-11-03 2019-12-31 Merck Patent Gmbh Rozpuszczalne białka fuzyjne inteiny i sposoby oczyszczania biocząsteczek
US11807671B2 (en) * 2016-11-16 2023-11-07 Auckland Uniservices Limited Methods for protein ligation and uses thereof
CN111073925B (zh) * 2018-10-19 2022-04-26 北京大学 一种基于无序蛋白偶联酶的高效多肽-多肽偶联系统和方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016112921A1 (en) 2015-01-15 2016-07-21 University Of Copenhagen Virus-like particle with efficient epitope display
JP2018521640A (ja) 2015-06-05 2018-08-09 オックスフォード ユニバーシティ イノベーション リミテッドＯｘｆｏｒｄ Ｕｎｉｖｅｒｓｉｔｙ Ｉｎｎｏｖａｔｉｏｎ Ｌｉｍｉｔｅｄ 融合タンパク質を合成するための方法および製品

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
Chem. Sci.，2017年，8，6577
Front. Bioeng. Biotechnol.，2020年，8:44
PLoS ONE，2016年，11(10)，e0165074
PLos ONE，2017年，12(6)，e0179740
PNAS，2012年，Vol. 109, No.12，E690-E697
Scientific Reports，2016年，6:19234
Scientific Reports，2017年，7:42753
Trends in Biochemical Sciences，2011年，Vol. 36, No. 4，pp. 229-237

Also Published As

Publication number Publication date
KR20230006473A (ko) 2023-01-10
CA3177709A1 (en) 2021-11-11
BR112022019632A2 (pt) 2023-10-03
EP4146675A1 (en) 2023-03-15
AU2021268757A1 (en) 2022-12-08
MX2022013938A (es) 2022-11-30
WO2021224451A9 (en) 2022-05-27
JP2023525752A (ja) 2023-06-19
JP2026048917A (ja) 2026-03-17
US20230321260A1 (en) 2023-10-12
CN115698045A (zh) 2023-02-03
WO2021224451A1 (en) 2021-11-11
IL297111A (en) 2022-12-01

Similar Documents

Publication Publication Date Title
JP7843245B2 (ja) ペプチドタグおよび結合パートナー
Brune et al. New routes and opportunities for modular construction of particulate vaccines: stick, click, and glue
CN110582566B (zh) 肽连接酶及其用途
US10197562B2 (en) Multiplex immuno screening assay
Zhao et al. Engineering the PP7 virus capsid as a peptide display platform
Greenwood et al. Multiple display of foreign peptides on a filamentous bacteriophage: peptides from Plasmodium falciparum circumsporozoite protein as antigens
JP6883529B2 (ja) 融合タンパク質を合成するための方法および製品
CN101084237B (zh) 用于治疗、诊断和色谱层析的泛蛋白或γ晶体缀合物
CN118580325A (zh) 自发性异肽键形成速率提高的蛋白质和肽标签及其用途
JP2018520675A (ja) ジユビキチン変異タンパク質をベースとした新規結合タンパク質及びその生成方法
CN108892723B (zh) 用于检测猪流行性腹泻病毒的单域重链抗体、制备方法及应用
JP4875497B2 (ja) バクテリオファージナノ粒子を含む方法および組成物
US11453886B2 (en) Virus-like particles and uses thereof
CN110551187A (zh) 化学合成的h7n9禽流感病毒na蛋白胞外区抗原片段及制备方法和应用
Ramirez et al. Engineering protein nanoparticles functionalized with an immunodominant Coxiella burnetii antigen to generate a Q fever vaccine
US20160000901A1 (en) Compositions and Methods for the Production of Virus-Like Particles
Craig et al. Polymeric display of proteins through high affinity leucine zipper peptide adaptors
CN119462963A (zh) 镜像偶联的蛋白质纳米颗粒缀合物及其应用
CN109758575B (zh) 充分多样的双亲性mhc ii结合多肽、免疫载体微球及其制备方法和应用
JPH08509613A (ja) 化学的に改変されたラムドイドバクテリオファージを用いる化合物の検出方法
CN116621947B (zh) 一种基于索烃骨架的拓扑蛋白质、制备方法及应用
JP2004043447A (ja) 蛋白質の製造方法
JP2006219401A (ja) 受容体を内包した分子会合体結晶とその製造方法およびその利用方法
KR101789056B1 (ko) Glutathione transferase (ＧＳＴ) 도메인으로 구성된 단백질 복합체 및 이의 용도
CN120283055A (zh) 异多聚体蛋白质的制造方法、蛋白质、核酸、表达载体、转化体、以及蛋白质的制造方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240501

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240501

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250513

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250813

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250902

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251219

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260224

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260302

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260310

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260330

R150 Certificate of patent or registration of utility model

Ref document number: 7843245

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150